VEGFC Protein (AA 103-227)

N° du produit ABIN2666942

Cette protéine Recombinant VEGFC est exprimée dans CHO Cells.

Aperçu rapide pour VEGFC Protein (AA 103-227) (ABIN2666942)

Antigène: VEGFC (Vascular Endothelial Growth Factor C (VEGFC))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: CHO Cells

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Pureté: > 98 % , as determined by Coomassie stained SDS-PAGE.

Détail du produit

Attributs du protein: AA 103-227

Stérilité: 0.22 μm filtered

niveau d'endotoxine:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: ED50 = 100 - 500 ng/ml, corresponding to a specific activity of 0.2 - 1.0 x 104 units/mg, as determined by the dose dependent stimulation of HUVEC cell proliferation.

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Détail du antigène

Antigène: VEGFC (Vascular Endothelial Growth Factor C (VEGFC))

Autre désignation: VEGF-C

Sujet: VEGF-C was initially cloned from human prostatic adenocarcinoma cell line PC-3 and human glioma G61 cell cDNA libraries. VEGF-C belongs to the VEGF family that includes the following members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs such as T.f. (Trimeresurus flavoviridis) and svVEGF (called VEGF-F) have been described. The homologus portions of VEGF-C are ~30 % identical to VEGF165, ~27 % to VEGF-B167, ~25 % to PlGF- 1, and ~22-24 % to PDGF-A and PDGF-B. VEGF-C possesses a C-terminal silk-protein-like structural motif (pattern of spacing cysteine residues) not present in other member of the VEGF family. VEGF-C binds to VEGFR3 that is almost exclusively expressed in lymphatic endothelium in adults, whereas in embryos (mid-gestation) it is expressed on blood vessels and is required for blood vascular remodeling. VEGFR3 is shared by VEGF-C and VEGF-D. VEGF-C is required for sprouting of the first lymphatic vessels from embryonic veins. Also, VEGF-C promotes survival of retinal vascular endothelial cells via VEGFR2. High levels of VEGF-C (in serum) have been associated to dyslipidemia and atherosclerosis. In addition, elevated levels of VEGF-C are increased in the serum of patients with some cancers (primary nonsmall cell lung carcinoma, cervical carcinoma, and gastric cancer among others) and it has been suggested that it is correlated with lymph node metastases and poor prognosis.

Poids moléculaire: The 135 amino acid recombinant protein has a predicted molecular mass of approximately 15.4 kDa. The DTT-reduced and non-reduced protein migrate at approximately 23-28 and 20-25 kDa by SDS-PAGE respectively. The N-terminal amino acid is Thr.

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2